Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Pulmonary Atelectasis D001261 1 associated lipids
Neurologic Manifestations D009461 1 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Brain Hemorrhage, Traumatic D020201 1 associated lipids
Migraine without Aura D020326 1 associated lipids
Mouth, Edentulous D009066 1 associated lipids
Anthrax D000881 1 associated lipids
Egg Hypersensitivity D021181 1 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Leukostasis D018921 1 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Capillary Leak Syndrome D019559 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Hemorrhagic Fever, American D006478 2 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Ileitis D007079 2 associated lipids
Peanut Hypersensitivity D021183 2 associated lipids
Jaundice, Obstructive D041781 2 associated lipids
Multiple Trauma D009104 2 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Ezoulin MJ et al. Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. 2006 Toxicol In Vitro pmid:16472967
Isobe J and Mizuno A Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. 1982 Tokushima J. Exp. Med. pmid:7170716
Inoue Y et al. Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. 1991 Tohoku J. Exp. Med. pmid:2063402
Nishihira J et al. Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets. 1985 Tohoku J. Exp. Med. pmid:3001971
Ou MC et al. Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. 1994 Thromb. Res. pmid:8191415
Le Blanc K et al. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. 1998 Thromb. Res. pmid:9772010
Siffert W et al. Inhibition of platelet aggregation by amiloride. 1986 Thromb. Res. pmid:3787567
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Bush LR and Smith SG Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. 1986 Thromb. Res. pmid:2948294
Belch JJ et al. Whole blood white cell aggregation: a novel technique. 1987 Thromb. Res. pmid:2448894
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
Nguyên P et al. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. 1995 Thromb. Res. pmid:7778064
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Violi F et al. Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate. 1989 Thromb. Res. pmid:2506658
Shukla SD et al. Hypersensitivity of diabetic human platelets to platelet activating factor. 1992 Thromb. Res. pmid:1329254
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Valone FH Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. 1987 Thromb. Res. pmid:3590086
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. 1987 Thromb. Res. pmid:3590110
Wade PJ et al. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. 1986 Thromb. Res. pmid:3961730
Karlsson H et al. Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. 1998 Thromb. Res. pmid:9694244
Cox CP and Wood KL Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. 1987 Thromb. Res. pmid:3629553
Catalán RE et al. Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. 1994 Thromb. Res. pmid:7974386
Ostermann G et al. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. 1987 Thromb. Res. pmid:3629555
Nishizawa EE and Della-Coletta AA The formation of a thrombin-like material (TLM) following stimulation of leukocytes. 1984 Thromb. Res. pmid:6484896
Valone FH Platelet-activating factor binding and metabolism during human platelet aggregation. 1988 Thromb. Res. pmid:3400077
Sloan IG and Firkin BG Impaired fibrinolysis in patients with thrombotic or haemostatic defects. 1989 Thromb. Res. pmid:2814943
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Pletscher A et al. LDL induced shape change reaction of platelets is not due to PAF. 1989 Thromb. Res. pmid:2609294
Cox CP Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. 1986 Thromb. Res. pmid:2421432
Croft KD and Beilin LJ Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. 1993 Thromb. Res. pmid:8385810
Vrzheshch PV et al. Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. 1992 Thromb. Res. pmid:1523610
Teng CM et al. Antiplatelet actions of some coumarin compounds isolated from plant sources. 1992 Thromb. Res. pmid:1523611
Joseph R et al. Platelet-activating factor and red blood cells. 1989 Thromb. Res. pmid:2734734
Ostermann G et al. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids. 1991 Thromb. Res. pmid:2028445
Joseph R et al. Endothelin-1 and human platelet activity. 1991 Thromb. Res. pmid:2028454
Tencé M et al. Ether-phospholipid composition in neutrophils and platelets. 1985 Thromb. Res. pmid:4024039
Hadváry P and Baumgartner HR Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. 1983 Thromb. Res. pmid:6868019
Tan EL and Snyder F Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. 1985 Thromb. Res. pmid:4024051
Garcia JG et al. Effect of platelet activating factor on leukocyte-endothelial cell interactions. 1988 Thromb. Res. pmid:2842887
Suzuki K et al. The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. 1980 Feb 1-15 Thromb. Res. pmid:6966083
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Ostermann G et al. Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. 1986 Thromb. Res. pmid:3764811
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
Avdonin PV et al. Evidence for the receptor-operated calcium channels in human platelet plasma membrane. 1987 Thromb. Res. pmid:2438805
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Csáki C et al. Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. 1992 Thromb. Res. pmid:1412179
May JA et al. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. 1997 Thromb. Res. pmid:9361371
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930